Every article, report, and earnings note where ISRG appears.
Intuitive Surgical posted 19% Q2 2026 revenue growth, driven by a larger da Vinci installed base and a recurring revenue mix that reached 85% of quarterly sales. The stock still earns only a Hold as a premium valuation limits upside despite strong operating momentum.
Intuitive Surgical, Inc. (ISRG) drops after investors reassess its post-earnings growth outlook. Despite strong Q2 results, slower procedure growth, tariff pressure, and a premium valuation are weighing on the stock.
The setbacks at Intuitive Surgical and HCA expose real pressure in elective procedures, but the evidence points more to coverage and payer mix than a broad healthcare demand collapse. UnitedHealth's guidance increase and Intuitive's maintained procedure outlook show why investors should separate marginal-patient exposure from underlying utilization.
Intuitive Surgical just got hit like the growth story broke, yet the quarter said the opposite. Revenue rose 19%, procedures stayed double-digit, and da Vinci 5 placements kept climbing, which makes this look more like an expectations reset than a business problem.
Intuitive Surgical, Inc. (ISRG) falls sharply after its Q2 2026 earnings report, even with an EPS beat. Investors focused on slower U.S. procedure growth and an unchanged outlook, triggering analyst target cuts and a valuation reset.
Intuitive Surgical, Inc. (ISRG) falls sharply after hours after its latest earnings release, even as procedure growth remains strong. The selloff reflects a high valuation, cautious analyst target cuts, and broader medtech weakness, leaving investors focused on whether the premium can hold.
Intuitive Surgical, Inc. (ISRG) drops sharply as investors de-risk ahead of earnings, while analyst target cuts and a risk-off market add pressure. The medtech leader remains fundamentally strong, but its premium valuation leaves the stock vulnerable to volatility before the July 16 report.
Intuitive Surgical trades at a premium because it is still delivering premium operating results. With procedure growth running around 17%, revenue up 20.5%, and the da Vinci installed base still expanding double digits, the usual "too expensive" knock misses what the business is actually doing.
Intuitive Surgical, Inc. (ISRG) rises sharply on above-average volume as investors react to strong procedure growth, da Vinci 5 adoption, and supportive sentiment. With no fresh earnings or FDA catalyst, the move appears tied to operating momentum, index-related flows, and renewed demand for quality healthcare growth.
Intuitive Surgical, Inc. (ISRG) drops sharply as investors rotate out of expensive healthcare growth stocks. The company’s fundamentals remain strong after a solid Q1 2026 report, but its premium valuation and margin concerns are pressuring the shares today.
Intuitive Surgical, Inc. (ISRG) rises after a strong Q1 2026 report topped profit and revenue expectations and lifted full-year procedure guidance. The move reflects investor confidence in the company’s recurring revenue model, durable demand for da Vinci systems, and continued growth in robotic-assisted surgery.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate ISRG ReportCancel anytime